ifosfamide has been researched along with Kidney Diseases in 95 studies
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 9.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 9.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 9.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma." | 7.77 | Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 7.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 6.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| " The male patient was enrolled into the research programme for the evaluation of the association between deletion of the genes encoding a number of classes of glutathione S-transferases (GST) and adverse reactions to alkylating agents." | 5.31 | Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in a 3-year-old boy whose genotype reveals the genes encoding glutathione S-transferases GSTM1 and GSTT1. ( Bodalski, J; Zielińska, E, 2001) |
| ", hypotension (which requires catecholamine support) results in unique nephrotoxicity in combination with select chemotherapeutic agents." | 5.30 | Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. ( Brauer, LP; Kriz, W; Pagel, H; Prieshof, B; Robins, HI; Schramm, U; Weiss, C; Wiedemann, GJ, 1998) |
| " The patients were treated between 1/1/1998 and 6/30/1999 according to the sarcoma protocols COSS-96, CWS-96, and EICESS-92, the median cumulative doses of the focussed drugs were for cisplatin: 360 mg/m(2), for doxorubicin: 270 mg/m(2), and for ifosfamide: 24 g/m(2)." | 5.11 | Late effects surveillance system for sarcoma patients. ( Beck, JD; Bielack, S; Langer, T; Paulussen, M; Stöhr, W; Treuner, J, 2004) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 5.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma." | 5.08 | [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997) |
| "Forty three patients with histologically confirmed malignant mesothelioma were entered onto an Eastern Cooperative Oncology Group phase II study of ifosfamide given with mesna." | 5.07 | An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. ( Borden, EC; Falkson, CI; Falkson, G; Hayes, JA; Hunt, M; Smith, TJ, 1992) |
| "Three patients with stage 4 neuroblastoma were treated with a schedule comprising alternating modules of myelosuppressive (ifosfamide, etoposide, doxorubicin) and less myelosuppressive (vincristine, cisplatin) drugs given every 10 days regardless of the neutrophil count." | 5.07 | Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin. ( Craft, AW; Lowis, SP; Pearson, AD; Reid, MM, 1993) |
| "We report on two children with rhabdomyosarcoma who received ifosfamide as part of their chemotherapy schedule." | 4.79 | Ifosfamide nephrotoxicity in children: histopathological features in two cases. ( Mann, JR; Milford, DV; Morland, BJ; Raafat, F; Stevens, MC, 1996) |
| "Ifosfamide is an alkylating agent, frequently used in the treatment of sarcoma." | 3.77 | Ifosfamide nephropathy in patients with sarcoma. ( Keikhaei, M; Mashhadi, MA; Sanadgol, H, 2011) |
| " The adverse effects of ifosfamide include proximal tubular damage, and renal wasting of electrolytes, glucose and amino acids, Fanconi syndrome, rickets and osteomalacia have also been reported with ifosfamide treatment." | 3.75 | Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children. ( Chayama, K; Fujieda, M; Hayashi, A; Matsunaga, A; Sekine, T; Tauchi, H, 2009) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 3.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| " In addition, the chemotherapeutic agent ifosfamide caused a decrease in plasma GPx activity in pediatric osteosarcoma patients." | 3.70 | Plasma glutathione peroxidase and its relationship to renal proximal tubule function. ( Avissar, N; Bhamre, S; Cohen, HJ; Ornt, DB; Salvatierra, O; Scandling, JD; Tham, DM; Tune, BM; Whitin, JC, 1998) |
| "The renal function of newly diagnosed children and young adults with high risk sarcomas was followed during therapy with a high dose ifosfamide-containing regimen." | 3.69 | A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. ( Balis, FM; Blaney, S; Ho, PT; Izraeli, S; Jarosinski, P; Weaver-McClure, L; Wexler, LH; Zimmerman, K, 1995) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 2.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin." | 2.69 | The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000) |
| "We report seven patients with germ cell tumors which either recurred following a minimum of two regimens of platinum-based chemotherapy or were refractory to cisplatin." | 2.67 | High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. ( Broun, ER; Einhorn, LH; Loehrer, PJ; Nichols, CR; Tricot, G; Williams, SD, 1991) |
| "Overall, childhood cancer survivors have a ninefold higher risk of developing renal failure compared with their siblings." | 2.58 | Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. ( Skinner, R, 2018) |
| " The toxic metabolite of IFO thought to be responsible for IFO-induced kidney damage is chloroacetaldehyde (CAA)." | 2.45 | Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention. ( Chen, N; Hanly, L; Koren, G; Rieder, M, 2009) |
| " However, this in vitro concentration of NAC needed to be compared to those used in human pharmacokinetic studies since the in vitro pharmacological effect of a compound is achieved at concentrations exceeding those used in clinical." | 2.44 | Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations. ( Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2007) |
| " Its main adverse effects are various forms of renal tubular and glomerular damage." | 2.40 | Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. ( Koren, G; Loebstein, R, 1998) |
| "Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)." | 2.39 | Strategies to prevent nephrotoxicity of anticancer drugs. ( Skinner, R, 1995) |
| "Renal dysfunction and urinary disorders are the most troublesome adverse reaction to anticancer agents such as cisplatin (CDDP) and ifosfamide (IFM)." | 2.38 | [New treatments for urogenital toxicity of anti-neoplastic chemotherapy]. ( Hirosawa, A; Niitani, H; Shibuya, M, 1990) |
| "With the increasing use of ifosfamide in pediatric malignancies, nephrotoxicity has emerged as a potentially serious adverse effect, which may be dose-limiting or may cause severe chronic morbidity, including glomerular impairment and/or Fanconi's syndrome." | 2.38 | Ifosfamide, mesna, and nephrotoxicity in children. ( Craft, AW; Pearson, AD; Sharkey, IM; Skinner, R, 1993) |
| "Ifosfamide is an alkylating agent, a synthetic analogue of cyclophosphamide, used to treat various solid cancers." | 1.62 | Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney. ( Choi, MS; Han, HY; Kim, SK; Kim, TW; Ko, JW; Yoon, S, 2021) |
| "Ifosfamide is a cytotoxic drug usually used in malignant sarcomas." | 1.48 | [Ifosphamide nephrotoxicity]. ( Ensergueix, G; Karras, A, 2018) |
| "Ifosfamide is an anticancer agent used largely in treatment of solid tumors." | 1.43 | Antioxidant activity of simvastatin prevents ifosfamide-induced nephrotoxicity. ( Ali, RM; Alkaraki, AK; Mhaidat, NM; Shotar, AM, 2016) |
| "Nephrotoxicity is a serious side effect associated with ifosfamide use." | 1.39 | N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. ( Hanly, L; Huang, SH; Koren, G; Regueira, O; Rieder, MJ; Shah, RK; Vasylyeva, TL, 2013) |
| "Data from 763 adult childhood cancer survivors (414 men) were obtained during regular visits at the late-effects clinic between 2003 and 2009." | 1.39 | Long-term nephrotoxicity in adult survivors of childhood cancer. ( Blijdorp, K; Cransberg, K; Dekkers, IA; Neggers, SJ; Pieters, R; Pluijm, SM; van den Heuvel-Eibrink, MM, 2013) |
| "Ifosfamide nephrotoxicity is a serious adverse effect for children undergoing cancer chemotherapy." | 1.35 | N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. ( Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2008) |
| "Patients with tubulopathy also had stunted growth in comparison with a control group of cancer patients without renal disease (mean difference at last examination: 7." | 1.34 | Growth impairment after ifosfamide-induced nephrotoxicity in children. ( Beck, JD; Kremers, A; Langer, T; Patzer, L; Paulides, M; Rossi, R; Stöhr, W, 2007) |
| "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO." | 1.33 | Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy. ( Benesic, A; Freudinger, R; Gekle, M; Groezinger, F; Kirchhoff, A; Mildenberger, S; Schwerdt, G; Wollny, B, 2006) |
| "Ifosfamide treatment significantly inhibited oxidative phosphorylation with only C-I substrates." | 1.33 | Ifosfamide-induced nephrotoxicity: mechanism and prevention. ( Daikhin, Y; Horyn, O; Luhovyy, B; Nissim, I; Phillips, PC; Yudkoff, M, 2006) |
| " The authors' multidimensional analysis model revealed that besides the total ifosfamide dose and co-administration of other toxic drugs, polymorphic locus of GSTP1 gene may be one of the factors determining a higher toxicity of the cytostatic agent." | 1.33 | Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. ( Misiura, K; Zielińska, E; Zubowska, M, 2005) |
| " The male patient was enrolled into the research programme for the evaluation of the association between deletion of the genes encoding a number of classes of glutathione S-transferases (GST) and adverse reactions to alkylating agents." | 1.31 | Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in a 3-year-old boy whose genotype reveals the genes encoding glutathione S-transferases GSTM1 and GSTT1. ( Bodalski, J; Zielińska, E, 2001) |
| "The renal functions in pediatric cancer patients who received ifosfamide (IFO) treatment were evaluated and the risk factors related to IFO nephrotoxicity were determined." | 1.31 | Ifosfamide nephrotoxicity in pediatric cancer patients. ( Ahn, HS; Cheong, HI; Choi, Y; Ha, IS; Hahn, H; Kang, HG; Lee, BS; Lee, JH; Shin, HY, 2001) |
| "Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults." | 1.30 | Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. ( Foxall, PJ; Hartley, JM; Lapsley, M; Neild, GH; Nicholson, JK; Singer, JM; Souhami, RL, 1997) |
| ", hypotension (which requires catecholamine support) results in unique nephrotoxicity in combination with select chemotherapeutic agents." | 1.30 | Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity. ( Brauer, LP; Kriz, W; Pagel, H; Prieshof, B; Robins, HI; Schramm, U; Weiss, C; Wiedemann, GJ, 1998) |
| " Its main adverse effects are various forms of renal tubular and glomerular damage." | 1.30 | Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. ( Atanackovic, G; Baruchel, S; Bishai, R; Gobrial, M; Hashemi, G; Ito, S; Khattak, S; Koren, G; Loebstein, R; Wolpin, J, 1999) |
| "The patients with prostatic cancer were treated with VIP (vincristine, ifosfamide, peplomycin) chemotherapy and the patients with urothelial cancer were treated with MP (methotrexate, cisplatinum) or MEP (methotrexate, Etoposide, cisplatinum) combination chemotherapy." | 1.29 | [Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer]. ( Kitamura, Y; Komatsubara, S; Sakata, Y; Watanabe, M, 1993) |
| " Dose-response curves for cisplatin (3-30 000 nmol) combined with non-toxic silibinin doses (7." | 1.29 | Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. ( Bokemeyer, C; Dunn, T; Fels, LM; Gaedeke, J; Lentzen, H; Schmoll, HJ; Stolte, H; Voigt, W, 1996) |
| "We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m2/course over 2 days in children with a diagnosis of malignant mesenchymal tumors." | 1.29 | Ifosfamide-induced renal tubular defect. ( López Pérez, J; Melero, C; Muley, R; Torres Valdivieso, MJ; Vara, J; Vivanco, JL, 1994) |
| " We observed this acute toxic effect despite the administration of sufficient mesna to prevent hemorrhagic cystitis." | 1.27 | Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. ( Goren, MP; Horowitz, ME; Pratt, CB; Wright, RK, 1987) |
| "Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum." | 1.26 | Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. ( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (15.79) | 18.7374 |
| 1990's | 44 (46.32) | 18.2507 |
| 2000's | 24 (25.26) | 29.6817 |
| 2010's | 11 (11.58) | 24.3611 |
| 2020's | 1 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Han, HY | 1 |
| Choi, MS | 1 |
| Yoon, S | 1 |
| Ko, JW | 1 |
| Kim, SK | 1 |
| Kim, TW | 1 |
| Skinner, R | 10 |
| Ruggiero, A | 1 |
| Ferrara, P | 1 |
| Attinà, G | 1 |
| Rizzo, D | 1 |
| Riccardi, R | 1 |
| Ensergueix, G | 1 |
| Karras, A | 1 |
| Schiavetti, A | 1 |
| Pedetti, V | 1 |
| Varrasso, G | 1 |
| Marrucci, O | 1 |
| Celani, C | 1 |
| Andreoli, G | 1 |
| Bonci, E | 1 |
| Dekkers, IA | 1 |
| Blijdorp, K | 1 |
| Cransberg, K | 1 |
| Pluijm, SM | 1 |
| Pieters, R | 1 |
| Neggers, SJ | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Hanly, L | 2 |
| Rieder, MJ | 1 |
| Huang, SH | 1 |
| Vasylyeva, TL | 1 |
| Shah, RK | 1 |
| Regueira, O | 1 |
| Koren, G | 9 |
| Shkalim-Zemer, V | 1 |
| Ash, S | 1 |
| Toledano, H | 1 |
| Kollender, Y | 1 |
| Issakov, J | 1 |
| Yaniv, I | 1 |
| Cohen, IJ | 1 |
| Mhaidat, NM | 1 |
| Ali, RM | 1 |
| Shotar, AM | 1 |
| Alkaraki, AK | 1 |
| Chen, N | 4 |
| Rieder, M | 3 |
| Fujieda, M | 1 |
| Matsunaga, A | 1 |
| Hayashi, A | 1 |
| Tauchi, H | 1 |
| Chayama, K | 1 |
| Sekine, T | 1 |
| Oberlin, O | 1 |
| Fawaz, O | 1 |
| Rey, A | 1 |
| Niaudet, P | 2 |
| Ridola, V | 1 |
| Orbach, D | 1 |
| Bergeron, C | 1 |
| Defachelles, AS | 1 |
| Gentet, JC | 1 |
| Schmitt, C | 1 |
| Rubie, H | 1 |
| Munzer, M | 1 |
| Plantaz, D | 1 |
| Deville, A | 1 |
| Minard, V | 1 |
| Corradini, N | 1 |
| Leverger, G | 1 |
| de Vathaire, F | 1 |
| Janeway, KA | 1 |
| Grier, HE | 1 |
| Parry, A | 1 |
| Price, L | 5 |
| Cole, M | 2 |
| Craft, AW | 8 |
| Pearson, AD | 8 |
| Mashhadi, MA | 1 |
| Sanadgol, H | 1 |
| Keikhaei, M | 1 |
| Caglar, K | 1 |
| Kinalp, C | 1 |
| Arpaci, F | 1 |
| Turan, M | 1 |
| Saglam, K | 1 |
| Ozturk, B | 1 |
| Komurcu, S | 1 |
| Yavuz, I | 1 |
| Yenicesu, M | 1 |
| Ozet, A | 1 |
| Vural, A | 1 |
| Kremens, B | 1 |
| Gruhn, B | 1 |
| Klingebiel, T | 1 |
| Hasan, C | 1 |
| Laws, HJ | 1 |
| Koscielniak, E | 1 |
| Hero, B | 1 |
| Selle, B | 1 |
| Niemeyer, C | 1 |
| Finckenstein, FG | 1 |
| Schulz, A | 1 |
| Wawer, A | 1 |
| Zintl, F | 1 |
| Graf, N | 1 |
| Langer, T | 3 |
| Stöhr, W | 3 |
| Bielack, S | 2 |
| Paulussen, M | 1 |
| Treuner, J | 2 |
| Beck, JD | 3 |
| Crews, KR | 1 |
| Liu, T | 1 |
| Rodriguez-Galindo, C | 1 |
| Tan, M | 1 |
| Meyer, WH | 2 |
| Panetta, JC | 1 |
| Link, MP | 1 |
| Daw, NC | 1 |
| Berrak, SG | 1 |
| Pearson, M | 1 |
| Berberoğlu, S | 1 |
| Ilhan, IE | 1 |
| Jaffe, N | 1 |
| Aleksa, K | 4 |
| Halachmi, N | 1 |
| Ito, S | 2 |
| Benesic, A | 2 |
| Schwerdt, G | 2 |
| Mildenberger, S | 2 |
| Freudinger, R | 2 |
| Gordjani, N | 1 |
| Gekle, M | 2 |
| Zielińska, E | 2 |
| Zubowska, M | 1 |
| Misiura, K | 1 |
| Paulides, M | 2 |
| Jürgens, H | 2 |
| Rossi, R | 3 |
| Patzer, L | 1 |
| Kremers, A | 1 |
| Nissim, I | 2 |
| Horyn, O | 1 |
| Daikhin, Y | 1 |
| Luhovyy, B | 1 |
| Phillips, PC | 1 |
| Yudkoff, M | 1 |
| Groezinger, F | 1 |
| Wollny, B | 1 |
| Kirchhoff, A | 1 |
| Woodland, C | 2 |
| Hilgard, P | 1 |
| Burkert, H | 1 |
| Brock, N | 1 |
| Stekar, J | 1 |
| Kreusser, W | 1 |
| Herrmann, R | 1 |
| Tschöpe, W | 1 |
| Ritz, E | 1 |
| Falkson, G | 3 |
| Van Dyk, JJ | 1 |
| Stapelberg, R | 1 |
| Falkson, HC | 1 |
| Holoye, PY | 1 |
| Duelge, J | 1 |
| Hansen, RM | 1 |
| Ritch, PS | 1 |
| Anderson, T | 1 |
| Torres Valdivieso, MJ | 1 |
| López Pérez, J | 1 |
| Melero, C | 1 |
| Vivanco, JL | 1 |
| Muley, R | 1 |
| Vara, J | 1 |
| Toma, S | 1 |
| Palumbo, R | 1 |
| Comandone, A | 1 |
| Oliva, C | 1 |
| Vincenti, M | 1 |
| Bumma, C | 1 |
| Rosso, R | 1 |
| Kitamura, Y | 1 |
| Watanabe, M | 1 |
| Komatsubara, S | 1 |
| Sakata, Y | 1 |
| Jones, DP | 1 |
| Chesney, RW | 1 |
| Anninga, JK | 1 |
| Valdés Olmos, RA | 1 |
| de Kraker, J | 2 |
| van Tinteren, H | 1 |
| Hoefnagel, CA | 1 |
| van Royen, EA | 1 |
| Hanquinet, S | 1 |
| Wouters, M | 1 |
| Devalck, C | 1 |
| Perlmutter, N | 1 |
| Sariban, E | 1 |
| Keir, MJ | 1 |
| Wyllie, RA | 2 |
| Coulthard, MG | 4 |
| Gödde, A | 1 |
| Kleinebrand, A | 1 |
| Riepenhausen, M | 1 |
| Boos, J | 1 |
| Ritter, J | 1 |
| Brandis, M | 2 |
| von der Hardt, K | 1 |
| Zimmerhackl, RB | 1 |
| Mohrmann, M | 1 |
| Leititis, J | 1 |
| De Schepper, J | 1 |
| Hachimi-Idrissi, S | 1 |
| Verboven, M | 1 |
| Piepsz, A | 1 |
| Otten, J | 1 |
| Stevens, MC | 2 |
| Sharkey, IM | 1 |
| Lowis, SP | 1 |
| Reid, MM | 1 |
| Morland, BJ | 1 |
| Mann, JR | 1 |
| Milford, DV | 1 |
| Raafat, F | 1 |
| Ho, PT | 1 |
| Zimmerman, K | 1 |
| Wexler, LH | 1 |
| Blaney, S | 1 |
| Jarosinski, P | 1 |
| Weaver-McClure, L | 1 |
| Izraeli, S | 1 |
| Balis, FM | 1 |
| English, MW | 1 |
| Bokemeyer, C | 2 |
| Fels, LM | 2 |
| Dunn, T | 1 |
| Voigt, W | 1 |
| Gaedeke, J | 1 |
| Schmoll, HJ | 1 |
| Stolte, H | 2 |
| Lentzen, H | 1 |
| Cachat, F | 1 |
| Guignard, JP | 1 |
| Baranzelli, MC | 1 |
| Pichon, F | 1 |
| Gourmel, B | 1 |
| N'Guyen, M | 1 |
| Deligny, N | 1 |
| Demaille, MC | 1 |
| Springate, JE | 1 |
| Tokuc, G | 1 |
| Yalçiner, A | 1 |
| Kebudi, R | 1 |
| Dogan, S | 1 |
| Görgün, O | 1 |
| Ayan, I | 1 |
| Suzuki, T | 1 |
| Nosaka, K | 1 |
| Morrison, SC | 1 |
| O'Donnell, JK | 1 |
| Loebstein, R | 2 |
| Koch Nogueira, PC | 1 |
| Hadj-Aïssa, A | 1 |
| Schell, M | 1 |
| Dubourg, L | 1 |
| Brunat-Mentigny, M | 1 |
| Cochat, P | 1 |
| Foxall, PJ | 1 |
| Singer, JM | 1 |
| Hartley, JM | 1 |
| Neild, GH | 1 |
| Lapsley, M | 1 |
| Nicholson, JK | 1 |
| Souhami, RL | 1 |
| Brauer, LP | 1 |
| Prieshof, B | 1 |
| Wiedemann, GJ | 1 |
| Weiss, C | 1 |
| Kriz, W | 1 |
| Schramm, U | 1 |
| Robins, HI | 1 |
| Pagel, H | 1 |
| Whitin, JC | 1 |
| Tham, DM | 1 |
| Bhamre, S | 1 |
| Ornt, DB | 1 |
| Scandling, JD | 1 |
| Tune, BM | 1 |
| Salvatierra, O | 1 |
| Avissar, N | 1 |
| Cohen, HJ | 1 |
| Ferrari, S | 1 |
| Zolezzi, C | 1 |
| Cesari, M | 1 |
| Fasano, MC | 1 |
| Lamanna, G | 1 |
| Bacci, G | 1 |
| Atanackovic, G | 1 |
| Bishai, R | 1 |
| Wolpin, J | 1 |
| Khattak, S | 1 |
| Hashemi, G | 1 |
| Gobrial, M | 1 |
| Baruchel, S | 1 |
| Hartmann, JT | 1 |
| Knop, S | 1 |
| van Vangerow, A | 1 |
| Kanz, L | 1 |
| Bodalski, J | 1 |
| Lee, BS | 1 |
| Lee, JH | 2 |
| Kang, HG | 1 |
| Hahn, H | 1 |
| Shin, HY | 1 |
| Ha, IS | 1 |
| Cheong, HI | 1 |
| Ahn, HS | 1 |
| Choi, Y | 1 |
| De Giorgi, U | 1 |
| Rosti, G | 1 |
| Papiani, G | 1 |
| Marangolo, M | 1 |
| Breitfeld, PP | 1 |
| Lyden, E | 1 |
| Raney, RB | 1 |
| Teot, LA | 1 |
| Wharam, M | 1 |
| Lobe, T | 1 |
| Crist, WM | 1 |
| Maurer, HM | 1 |
| Donaldson, SS | 1 |
| Ruymann, FB | 1 |
| Lewis, LD | 1 |
| Burton, LC | 1 |
| Harper, PG | 1 |
| Rogers, HJ | 1 |
| Hunt, M | 2 |
| Borden, EC | 1 |
| Hayes, JA | 1 |
| Falkson, CI | 1 |
| Smith, TJ | 1 |
| Shore, R | 1 |
| Greenberg, M | 1 |
| Geary, D | 1 |
| Broun, ER | 1 |
| Nichols, CR | 1 |
| Tricot, G | 1 |
| Loehrer, PJ | 2 |
| Williams, SD | 2 |
| Einhorn, LH | 3 |
| Heney, D | 1 |
| Wheeldon, J | 1 |
| Rushworth, P | 1 |
| Chapman, C | 1 |
| Lewis, IJ | 1 |
| Bailey, CC | 1 |
| Suarez, A | 1 |
| McDowell, H | 1 |
| Comoy, E | 1 |
| Flamant, F | 1 |
| Caron, HN | 1 |
| Abeling, N | 1 |
| van Gennip, A | 1 |
| Voûte, PA | 1 |
| Vogelzang, NJ | 1 |
| Elias, AD | 1 |
| Ayash, LJ | 1 |
| Eder, JP | 1 |
| Wheeler, C | 1 |
| Deary, J | 1 |
| Weissman, L | 1 |
| Schryber, S | 1 |
| Critchlow, J | 1 |
| Schnipper, L | 1 |
| Antman, KH | 1 |
| Elias, A | 1 |
| Ryan, L | 1 |
| Shibuya, M | 1 |
| Hirosawa, A | 1 |
| Niitani, H | 1 |
| Goren, MP | 3 |
| Pratt, CB | 3 |
| Wright, RK | 3 |
| Dodge, RK | 1 |
| Viar, MJ | 1 |
| Lauer, R | 1 |
| Roth, BJ | 1 |
| Kalasinski, LA | 1 |
| Horowitz, ME | 2 |
| Patterson, WP | 1 |
| Khojasteh, A | 1 |
| Wiltshaw, E | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Fisher, C | 1 |
| Alberts, AS | 1 |
| Van Zyl, L | 1 |
| Ghosn, M | 1 |
| Droz, JP | 1 |
| Theodore, C | 1 |
| Pico, JL | 1 |
| Baume, D | 1 |
| Spielmann, M | 1 |
| Ostronoff, M | 1 |
| Moran, A | 1 |
| Salloum, E | 1 |
| Kramar, A | 1 |
19 reviews available for ifosfamide and Kidney Diseases
| Article | Year |
|---|---|
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; N | 2018 |
Renal toxicity and chemotherapy in children with cancer.
Topics: Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Inciden | 2017 |
Ifosfamide nephrotoxicity in children: a mechanistic base for pharmacological prevention.
Topics: Acetaldehyde; Acetylcysteine; Age Factors; Antineoplastic Agents, Alkylating; Antioxidants; Child; H | 2009 |
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
Chronic ifosfamide nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Chronic Disease; Humans; Ifosfamide; Kidney Diseases; Neop | 2003 |
Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations.
Topics: Acetylcysteine; Humans; Ifosfamide; Kidney Diseases | 2007 |
Nephrological complications of cancer therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Humans; Ifosfamide; Kidney; | 1982 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human | 1995 |
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Topics: Child; Cisplatin; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tu | 1995 |
Cytostatics--induced tubular toxicity.
Topics: Antineoplastic Agents; Cisplatin; Humans; Ifosfamide; Kidney Diseases; Kidney Tubules; Methotrexate; | 1993 |
Ifosfamide, mesna, and nephrotoxicity in children.
Topics: Child; Humans; Ifosfamide; Kidney Diseases; Mesna; Risk Factors | 1993 |
Ifosfamide nephrotoxicity in children: histopathological features in two cases.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Child; Child, Preschool; Female; Humans; Ifosfamid | 1996 |
[The kidney in children under chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Child; Cisplatin; Glomerular | 1996 |
Toxic nephropathies.
Topics: Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Huma | 1997 |
[Nephrotoxicity of antineoplastic drugs].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1997 |
Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dose-Res | 1998 |
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical T | 2002 |
Nephrotoxicity from chemotherapy: prevention and management.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr | 1991 |
[New treatments for urogenital toxicity of anti-neoplastic chemotherapy].
Topics: Antidotes; Antineoplastic Agents; Cisplatin; Humans; Ifosfamide; Kidney Diseases; Mesna; Thiosulfate | 1990 |
14 trials available for ifosfamide and Kidney Diseases
| Article | Year |
|---|---|
Long-term renal function and hypertension in adult survivors of childhood sarcoma: Single center experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Body Mass Index; Child; Child, Preschool; Cros | 2018 |
Late effects surveillance system for sarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Doxorubicin; Feasibili | 2004 |
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Bone Neoplasms; Child; Child, Presc | 2004 |
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm | 1995 |
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Child, Preschool; C | 1993 |
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations | 1997 |
Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1998 |
Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa | 2000 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Topics: Drug Administration Schedule; Female; Humans; Ifosfamide; Infusions, Intravenous; Kidney Diseases; M | 1992 |
High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1991 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil | 1990 |
62 other studies available for ifosfamide and Kidney Diseases
| Article | Year |
|---|---|
Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney.
Topics: Animals; Chemical and Drug Induced Liver Injury; Gene Expression Regulation; Ifosfamide; Kidney; Kid | 2021 |
[Ifosphamide nephrotoxicity].
Topics: Adult; Antineoplastic Agents, Alkylating; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Ki | 2018 |
Long-term nephrotoxicity in adult survivors of childhood cancer.
Topics: Adolescent; Adult; Albuminuria; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Chemotherap | 2013 |
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
Topics: Acetylcysteine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Antioxidants; Child; Drug Adm | 2013 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Antioxidant activity of simvastatin prevents ifosfamide-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Creatinine; Cytoprotection; Disease Models, Animal; Ifosfamide; K | 2016 |
Children's toxicology from bench to bed--Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children.
Topics: Adolescent; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cisplatin; Dose-Response Rel | 2009 |
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise | 2009 |
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female | 2010 |
Ifosfamide nephropathy in patients with sarcoma.
Topics: Adolescent; Adult; Age Distribution; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coh | 2011 |
Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Agents, Alkyla | 2002 |
High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modal | 2002 |
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu | 2005 |
Renal ontogeny of ifosfamide nephrotoxicity.
Topics: Acetaldehyde; Age Factors; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases | 2004 |
Disturbed Ca2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Calcium; Calcium Signaling; Calcium-Transporting AT | 2005 |
Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Cyclophosph | 2005 |
Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Topics: Abdomen; Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2007 |
Growth impairment after ifosfamide-induced nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Body Height; Child; Child, Preschool; Female; Glomeru | 2007 |
Ifosfamide-induced nephrotoxicity: mechanism and prevention.
Topics: Acetaldehyde; Agmatine; Animals; Antineoplastic Agents, Alkylating; Drug Interactions; Electron Tran | 2006 |
Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Biomarkers; Caspase 3; Caspase 8; Cathepsin B; Cell | 2006 |
Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment.
Topics: Amphotericin B; Child; Cyclosporine; Humans; Ifosfamide; Kidney Diseases; Kidney Function Tests; Tim | 2007 |
N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Alkylating; beta 2-Microglobulin; Creatinine; Diseas | 2008 |
Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
Topics: Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidney Diseases; Mercaptoethanol; Mesna | 1984 |
[Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Topics: Animals; Cyclophosphamide; Ifosfamide; Kidney Diseases; Mercaptoethanol; Mesna; Oxidation-Reduction; | 1982 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap | 1982 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
Ifosfamide-induced renal tubular defect.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Doxorubicin; Humans; | 1994 |
[Comparative study on urinary parameters reflecting renal damage during chemotherapy for urological cancer].
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherap | 1993 |
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, | 1994 |
Increased renal parenchymal echogenicity in ifosfamide-induced renal Fanconi syndrome.
Topics: Child; Child, Preschool; Fanconi Syndrome; Female; Humans; Ifosfamide; Infant; Kidney Diseases; Ultr | 1995 |
Inaccuracy of glomerular filtration rate estimation from height/plasma creatinine ratio.
Topics: Adolescent; Body Height; Child; Child, Preschool; Cisplatin; Creatinine; Female; Glomerular Filtrati | 1994 |
Ifosfamide nephrotoxicity in children.
Topics: Glomerular Filtration Rate; Humans; Ifosfamide; Infant; Kidney Diseases | 1994 |
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Infant; | 1994 |
Renal function abnormalities after ifosfamide treatment in children.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Ifosfamide; Kidney Dis | 1993 |
Incidence and etiology of ifosfamide nephrotoxicity: report of a meeting held in Rhodes, Greece, October 3, 1991, sponsored by Asta Medica, Frankfurt, Germany.
Topics: Child; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Humans; Ifosfamide; Incidence; | 1993 |
A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; beta 2-Microglobulin; Child; Child, Preschool; | 1995 |
Risk factors for ifosfamide nephrotoxicity in children.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Ifo | 1996 |
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Disease Models, A | 1996 |
Renal dysfunctions secondary to ifosfamide treatment in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dose-Response Relationship, | 1997 |
Ifosfamide-induced alteration of technetium-99m-DMSA renal parenchymal imaging.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; I | 1997 |
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Whole-body hyperthermia combined with ifosfamide and carboplatin causes hypotension and nephrotoxicity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 1998 |
Plasma glutathione peroxidase and its relationship to renal proximal tubule function.
Topics: Adult; Animals; Antibodies; Cephaloglycin; Child; Creatinine; Fanconi Syndrome; Glutathione Peroxida | 1998 |
Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Drug Adm | 1999 |
Growth retardation and osteomalacia as a result of ifosfamide nephrotoxicity in a 3-year-old boy whose genotype reveals the genes encoding glutathione S-transferases GSTM1 and GSTT1.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; | 2001 |
Ifosfamide nephrotoxicity in pediatric cancer patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cisplatin; Female; Humans; I | 2001 |
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Ki | 1992 |
Iphosphamide-induced nephrotoxicity in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant; | 1992 |
Progressive renal toxicity due to ifosfamide.
Topics: Acetylglucosaminidase; Albuminuria; Alpha-Globulins; Child; Child, Preschool; Female; Follow-Up Stud | 1991 |
Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presc | 1991 |
Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens.
Topics: Alanine Transaminase; Amino Acids; Aspartate Aminotransferases; Carboplatin; Child; Child, Preschool | 1992 |
Nephrotoxicity after ifosfamide.
Topics: Adolescent; Albuminuria; Bone and Bones; Child; Child, Preschool; Cross-Sectional Studies; Female; G | 1990 |
Mesna excretion and ifosfamide nephrotoxicity in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; | 1989 |
Nephrotoxicity of ifosfamide in children.
Topics: Adolescent; Child; Humans; Ifosfamide; Kidney Diseases | 1989 |
Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etopo | 1988 |
Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein.
Topics: Antineoplastic Agents; Carrier Proteins; Child; Child, Preschool; Dipeptidyl Peptidase 4; Humans; If | 1986 |
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aminopeptidases; CD13 Antigens; Child; Child, Preschool; C | 1987 |
Ifosfamide-induced renal tubular defects.
Topics: Hematuria; Humans; Hydrogen-Ion Concentration; Ifosfamide; Kidney Diseases; Kidney Tubules; Lymphoma | 1989 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
Topics: Adolescent; Adult; Aged; Drug Evaluation; Female; Humans; Ifosfamide; Kidney Diseases; Male; Mercapt | 1988 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etopo | 1988 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn | 1986 |